To study the role of atypical protein kinase C (aPKC) in neurodegenerative disease, we investigated the distribution of PKCI/L, an aPKC isoform, in a variety of tauopathies and >-synucleinopathies. Immunohistochemical study revealed PKCI/L within tau-positive neurofibrillary inclusions in Alzheimer disease (AD), progressive supranuclear palsy, corticobasal degeneration (CBD), and Pick disease (PiD), within >-synuclein-positive Lewy bodies in idiopathic Parkinson disease and dementia with Lewy bodies, as well as within glial inclusions in multisystem atrophy. We also observed PKCI/L label of actin-rich Hirano bodies in AD, PiD, and elderly individuals. Double immunolabeling and fluorescence resonance energy transfer demonstrated close physical association between PKCI/L and phospho-tau or >-synuclein in some neurofibrillary tangles and Lewy bodies. Furthermore, PKCI/L colocalized with p62, a chaperone protein that binds to both aPKC and ubiquitin, in most of these inclusions. PKCI/L also closely associated with the inactivated form of glycogen synthase kinase-3A, GSK-3A[ser9]. Together, these findings suggest that PKCI/L may play a role in common mechanisms involving the pathogenesis of neurodegenerative disease.
INTRODUCTION
Abnormal filamentous protein aggregates (intracellular inclusions) are hallmarks of many neurodegenerative diseases. Hyperphosphorylated tau comprises paired helical filaments (PHFs) in neurofibrillary tangles (NFTs) in Alzheimer disease (AD); globose tangles and glial inclusions in progressive supranuclear palsy (PSP); neuronal and glial inclusions in corticobasal degeneration (CBD); and Pick bodies in Pick disease (PiD) (1Y3). Alpha-synuclein is a major constituent of Lewy bodies in Parkinson disease (PD) and dementia with Lewy bodies (DLB) (4) , as well as glial inclusions in multisystem atrophy (MSA) (5) . Hirano bodies, commonly seen in hippocampal pyramidal neurons in aging, AD, and PiD, consist mainly of actin and actinassociated proteins (6) . The remarkable heterogeneity and overlap of neurologic disorders displaying these inclusions are well recognized (1, 7, 8) and argue for common mechanisms of pathogenesis.
A number of potentially important molecules have been associated with these protein aggregates. For example, ubiquitin is abundant in both tau-and >-synuclein-related inclusions (9) , and malfunction of the ubiquitinYproteasome system has been implicated in inclusion formation, especially in the formation of Lewy bodies (10) . Protein kinases such as glycogen synthase kinase 3A (GSK-3A), mitogen-activated protein kinases, protein kinase A, calcium/calmodulin dependent kinase II (CaMKII), and cyclin-dependent kinase 5 have been found in association with tauopathies (11Y15), and their roles in hyperphosphorylating tau are believed to be critical to inclusion formation. Additionally, protein kinases may become Bentrapped[ in abnormal protein aggregates and lose their ability to phosphorylate normal substrates. Because many kinase activities are vital to key cellular functions, the Bentrapment[ or disabling of a given kinase in various inclusions may, in and of itself, underlie a common pathophysiological process in different diseases.
Atypical protein kinase C (aPKC) isoforms are derived from 2 known genes: X and I/L (I refers to the human isoform, whereas L refers to its rodent homologue). aPKC differs from conventional and novel PKCs by the absence of functional calcium and diacylglycerol (DAG) binding elements in the regulatory domain (16, 17) . aPKC has been shown to play a critical role in cellular differentiation and polarity (18) , glucose transport and utilization (19) , and growth promotion and anti-apoptosis in neurons (20, 21) . As discussed in detail in the accompanying report (22) , the brain-specific X isoform, PKMX (the independent catalytic domain of PKCX), has been shown both necessary and sufficient for maintaining long-term potentiation in rodents (23, 24) and for memory enhancement in Drosophila (25).
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The second isoform, PKCI/L, has been shown to play a critical role in growth factor-dependent survival and differentiation of cultured neuronal cells (26) . Both isoforms may be important for establishing and maintaining cell polarity in a variety of cell types, including neurons (27) . This article focuses on the distribution and potential role of PKCI/L in neurodegenerative disease.
MATERIALS AND METHODS

Postmortem Human Brain Tissue
Autopsy brain tissue was derived from neuropathologically confirmed cases of neurodegenerative diseases and controls listed in Table 1 . The 6 cases of Bpure[ AD as well as the 14 cases of AD and dementia with Lewy bodies all met CERAD neuropathologic criteria for definite AD (28, 29) . The 3 PiD cases had classic neuropathologic features of this disorder, including frontotemporal atrophy, abundant taupositive Pick bodies within neurons, including the granular cell and pyramidal cell layer of hippocampus, and Pick cells (30) . The 5 cases of CBD, previously published (7), met current neuropathologic criteria for this disorder (1) with abundant tau-immunoreactive lesions, including astrocytic plaques, degeneration of cortex and nigra, and neurofilament protein-positive ballooned neurons. The 9 cases of PSP displayed the classic histopathologic features of PSP, including tau-positive globose NFTs (2); these changes occurred in a stereotypical distribution (31) . The neuropathologic diagnoses of dementia with Lewy body cases conformed to consensus criteria of McKeith et al (32) . The 2 cases of idiopathic PD presented clinically with classic L-dopa-responsive parkinsonism, and autopsy demonstrated nigral degeneration with >-synuclein-positive Lewy bodies in the substantia nigra and other sites. The 3 cases of MSA all exhibited striatonigral degeneration with 2 of the 3 also showing olivocerebellar pontine atrophy. The classic ubiquitin and >-synuclein-positive but taunegative glial cytoplasmic inclusions within oligodendroglial cells (33) were found in all 3 cases. The 5 control cases were derived from patients aged 60 to 96 years with no clinical history of dementia as described in the accompanying paper (22) . One case was Braak stage I, 2 cases were Braak stage II, and 2 were Braak stage IIIYIV. Sections of hippocampus, entorhinal cortex, amygdala, and temporal cortex from these control cases were used in this study. Table 2 lists the primary antibodies used in this study. The mouse anti-PKCI (human) and mouse anti-PKCL (rodent), widely used by others in rodent tissue (26, 34, 35) , both recognize human PKCI protein and showed identical results in this study. Thus, these antisera are referred to collectively as Banti-PKCI/L[ in this article. As we illustrate in the Western blot in the accompanying report (22) , human brain homogenates from the superior temporal cortex, hippocampus, caudate nucleus, and cerebellum, the PKCI/L antibody recognized a single 72-kD band compared with the 
Antibodies
Immunohistochemistry
Formalin-fixed, paraffin-embedded sections (8 Km) were deparaffinized in xylene and rehydrated. To enhance antigen retrieval, sections were microwaved in a microwavable pressure cooker (Black and Decker, Hampstead, MD) in 0.1 M citrate buffer at pH 6.0 until the pressure cooker reached full pressure. The sections were microwaved for an additional 5 minutes, kept standing until the solution reached room temperature, and then treated with 95% formic acid for 2 minutes. Endogenous peroxidase activity was blocked by incubating the sections in 3% H 2 O 2 in phosphate-buffered saline for 20 minutes. The sections were incubated for 30 minutes in blocking solution comprised of 10% horse serum in a detergent of phosphate-buffered saline with surfactant (Optimax Wash Buffer; BioGenex, San Ramon, CA). Then, the sections were incubated overnight with the respective primary antibodies in buffer at dilutions listed in Table 2 . After 3 5-minute washes in buffer, the sections were incubated with the secondary horse antirabbit/ mouse IgG (Vector Laboratories, Burlingame, CA) in buffer for 30 minutes. The sections were washed as previously described and incubated in R.T.U. Vectastain Elite ABC reagent (Vector Laboratories) for 30 minutes, washed in buffer, and developed with 6.7% diaminobenzidine (DAB; Sigma-Aldrich, St. Louis, MO) reaction in the presence of 0.03% H 2 0 2 . The sections were then counterstained with hematoxylin, cleared in xylene, mounted with Cytoseal 60 mounting medium (Richard-Allan Scientific, Kalamazoo, MI), and coverslipped.
For double-immunofluorescence, sections were incubated overnight at 4-C in a cocktail of the mouse anti-PKCI/L antibody and one of the following polyclonal antibodies: rabbit anti-phospho-tau, anti->-synuclein, anti-ubiquitin, or anti-GSK-3A
Fluorescence Resonance Energy Transfer
To ascertain the proximity between 2 molecules (e.g. PKCI/L and phosphotau), we took advantage of the fluorescence resonance energy transfer (FRET) technique as applied by Hyman and colleagues (37, 38) . This method depends on the ability of 2 fluorochromes (labeling 2 different antigens) to act as fluorescent donorYacceptor pairs. For this to work, the absorption spectra of the acceptor, in this study Alexa Fluor 568, must overlap the emission spectra of the donor, in this study, Alexa Fluor 488. If the 2 fluorochromes are in close proximity (less than 10 nm), photons from excited donor molecules will transfer to acceptor molecules, quenching the fluorescent emission of the donor. FRET is demonstrated, in principle, when an increase in donor intensity follows photobleaching of the acceptor. Double-immunofluorescence-labeled sections were examined with a BioRad MRC-1024 confocal microscopic system equipped with a krypton/argon laser. After taking initial images at the 2 wavelengths, a portion of the Alexa Fluor 568 image was magnified and subjected to higher laser power bleaching. Then, comparable images were collected again at both wavelengths. FRET was demonstrated when photobleaching of the acceptor produced an increase in intensity of the donor. Control sections stained only with Alexa Fluor 488 failed to elicit FRET.
RESULTS
PKCI/L Immunoreactivity in Tauopathies and >-Synucleinopathies
PKCI/L immunoreactivity, of mild intensity, in a finely granular pattern was noted within neuronal cell bodies and neuropil in a widespread distribution (Fig. 1A) in control tissues as well as in uninvolved areas of disease cases. Ependymal cells and choroid plexus epithelial cells were also immunoreactive; astrocytes and corpora amylacea failed to label (data not shown). This pattern is similar to that reported in rodents (35) .
In AD, antibody to PKCI/L strongly labeled many NFTs in the hippocampus (Fig. 1B) , neocortex, subcortical gray matter, and brainstem. The antibody also labeled most Hirano bodies in CA1 of the hippocampus (Fig. 1C) The PKCI/L antibody uniformly labeled Pick bodies in neurons of hippocampal dentate gyrus and neocortex of PiD (Fig. 1D) . In cases of PSP, the antibody labeled globose tangles and tufted astrocytes in the subthalamic, mesencephalic, inferior olivary, and cerebellar dentate nuclei (Fig. 1E, F) . In CBD, tau-immunoreactive astrocytic inclusions in cerebral cortex, as well as neuronal and glial inclusions in the basal ganglia, were immunopositive (Fig. 1G) . In the >-synucleinopathies, the PKCI/L antibody strongly labeled all classic Lewy bodies found in the substantia nigra as well as the majority of Lewy bodies in the cerebral cortex and amygdala in PD and DLB (Fig. 1H, I ). Lewy neurites in the amygdala, hippocampus CA2/3, and midbrain were not labeled. The PKCI/L antibody also labeled some glial >-synuclein-positive inclusions in MSA (Fig. 1J) . Omission of the primary antibody resulted in no immunolabeling of any of these structures (Fig. 1K) . The labeling of the PKCI/L antibody was similar to that of the pan-aPKC antibody, which further confirmed the presence of aPKC in tauopathies and >-synucleinopathies (Table 3 ). The pan-aPKC antibody also labeled dystrophic neurites and Lewy neurites, likely reflecting the distribution of PKMX present in a subset of NFTs and neurites as described in the accompanying report (22) .
Colocalization of PKCI/L With Phospho-Tau and >-Synuclein
Confocal microscopy of double-immunolabeled tissue revealed that PKCI/L variably colocalized with phospho-tau in inclusions of tauopathies: NFTs in AD, Pick bodies in PiD, and globose tangles and glial inclusions in PSP (Fig. 2AYD) . In some of these structures, the distribution of PKCI/L was identical to that of phospho-tau; in such instances, FRET was demonstrated (Fig. 2EYH) , suggesting a close proximity between the 2 molecules. In other inclusions in these tauopathies, however, the distribution and colocalization of PKCI/L and phospho-tau immunoreactivity were more variable. PKCI/L immunoreactivity also was associated with >-synuclein and ubiquitin immunoreactivity in Lewy bodies (Fig. 3AYD) . Interestingly, classic Lewy bodies in the substantia nigra exhibited PKCI/L immunoreactivity in their Bcores[ with >-synuclein and ubiquitin immunoreactivity at the periphery (Fig. 3A, B) . BPale[ Lewy bodies, seen occasionally in the midbrain and thought to represent Bearly[ Lewy bodies (39) , were diffusely labeled by both PKCI/L and >-synuclein antibodies (Fig. 3C, EYH) . Similarly, cortical Lewy bodies exhibited diffuse labeling by both antibodies (Fig. 3D) . The close association between PKCI/L and >-synuclein in the pale Lewy bodies was further demonstrated by FRET (Fig. 3EYH ) in a manner similar to that between PKCI/L and phospho-tau shown for NFTs (Fig. 2EYH) .
Colocalization of PKCI/L With p62 and Ubiquitin in Inclusions
p62, a ubiquitin-binding protein, has been demonstrated within various inclusions in tauopathies and >-synucleinopathies (40, 41) . Because p62 is also an atypical PKC-interacting Because GSK-3A is regarded as a major kinase responsible for tau phosphorylation and PHF formation (44), we examined the relationship between PKCI/L and GSK-3A. We found that PKCI/L colocalized with the inactivated form of GSK-3A[ser9] in most NFTs in AD in all areas examined (Fig. 5) . A close association between the 2 molecules was demonstrated by FRET (data not shown).
DISCUSSION
We have found that PKCI/L, an isoform of aPKC, is associated with a wide array of intracellular inclusions and structures in neurodegenerative diseases, including 1) taupositive neuronal and glial inclusions in tauopathies (i.e. AD, PSP, PiD, and CBD; 2) Lewy bodies and glial inclusions in >-synucleinopathies (i.e. PD, DLB and MSA); and 3) actin-rich Hirano bodies (Table 3) . PKCI/L is present in all classic Lewy bodies found in the substantia nigra and in many cortical Lewy bodies, Hirano bodies, Pick bodies, and NFTs. Interestingly, the presence of aPKC, including PKCI/L and PKMX, in NFTs is unique among PKC subgroups, because a panel of isoform-specific antibodies to conventional and novel PKCs failed to label any NFTs in AD (22, 45, 46) .
The association of PKCI/L with neuropathologic features of neurodegenerative disease is more widespread than that of other protein kinases such as GSK-3A, Cdk5, MAPKs, PKA, and CaMKII; most of these kinases are associated with either tauopathies or >-synucleinopathies. The distribution of PKCI/L in pathologic structures in these disorders largely parallels that of ubiquitin, although ubiquitin has not been identified in Hirano bodies (47) . The ubiquitin-binding protein, p62, has been shown to occur in inclusions of both tauopathies and >-synucleinopathies as well as in Mallory bodies in the liver (40, 41) . Our data show that PKCI/L and p62, along with ubiquitin, are colocalized in many inclusions, suggesting that PKCI/L may interact with ubiquitin and ubiquitin-binding proteins during abnormal protein aggregation. Furthermore, the association between PKCI/L and p62 within neuropathologic structures described in this study is intriguing given recent data showing that p62 acts as a scaffolding protein, mediating interactions between neurotrophin receptors and nuclear factor kappa B (NF-JB), a transcription factor thought to play a role in anti-apoptosis and neuronal survival (26, 42, 48) .
The variable pattern of colocalization of PKCI/L with phospho-tau or >-synuclein as well as with p62 and ubiquitin may reflect dynamic interactions between these molecules (49) and PKCI/L. For example, Bpale[ Lewy bodies, often regarded as precursors to classic Lewy bodies (39), exhibit diffuse labeling by both PKCI/L and >-synuclein, whereas classic Lewy bodies exhibit disparate localization of the 2 molecules. It is conceivable that PKCI/L first interacts with >-synuclein, playing a role in its phosphorylation (50) , and then segregates as Lewy body formation progresses.
Impairment of PKCI/L activity may contribute indirectly to the formation of NFTs. It is known that PKC, including aPKC, are capable of phosphorylating and inactivating GSK-3A during insulin-dependent glucose transport (43) . Because GSK-3A plays a key role in tau phosphorylation in neurons, its inactivation by aPKC may reduce tau phosphorylation. In an in vivo study, injection of PKC inhibitors into the lateral ventricles of rat brains led to overactivation of GSK-3A, hyperphosphorylation of tau, and impaired spatial memory (51) . Indeed, because aPKC are the only isoforms within the PKC family present in NFTs, aPKC is a likely candidate for mediating phosphorylation of GSK-3A on serine 9. Of the 2 aPKC isoforms, X and I/L, PKCI/L is more likely to be the molecule regulating GSK-3A because PKCX is undetectable in the forebrain region (35) and its truncated form, PKMX, is present in smaller numbers of NFTs with a restricted distribution (22) . The close association of PKCI/L with the inactivated GSK-3A[ser9] in NFTs that we describe further supports this notion. Thus, PKCI/L may belong to a group of kinases, including Akt/PKB and PKN, that occur in NFTs and are capable of phosphorylating GSK-3A (52, 53) .
In addition to having an active role in inclusion formation, PKCI/L also may be Bentrapped[ in various filamentous protein aggregates, thereby losing its ability to phosphorylate normal substrates. Whether sequestration of PKCI/L by protein aggregates in neurodegenerative diseases impedes its response to growth factors and/or affects other critical functions in neurons remains to be explored.
In summary, we have demonstrated the association of PKCI/L with a wide array of intracellular inclusions in tauopathies and >-synucleinopathies, suggesting that PKCI/L plays a broad role in neurodegenerative disease. Further investigations are warranted to determine whether PKCI/L contributes to phosphorylation during abnormal protein aggregation and whether interactions between PKCI/L and various protein aggregates result in the disruption of the normal cellular functions of this important form of PKC.
